Events

Learn about Octapharma’s IVIg therapy and the results of the landmark Progress in Dermatomyositis (ProDERM) study. The successful ProDERM Study resulted in the first and only FDA-approved IVIg therapy for DM in adults. MSU and Octapharma USA are proud to co-sponsor this exciting educational program with Dr. Rohit Aggarwal.